Y Intercept Hong Kong Ltd Buys New Position in Merit Medical Systems, Inc. $MMSI

Y Intercept Hong Kong Ltd acquired a new position in Merit Medical Systems, Inc. (NASDAQ:MMSI) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 42,347 shares of the medical instruments supplier’s stock, valued at approximately $2,919,000.

A number of other hedge funds have also modified their holdings of the stock. Los Angeles Capital Management LLC acquired a new position in shares of Merit Medical Systems in the 4th quarter valued at $25,000. Maseco LLP purchased a new stake in Merit Medical Systems during the fourth quarter valued at about $26,000. Torren Management LLC acquired a new position in shares of Merit Medical Systems in the fourth quarter worth about $38,000. Covestor Ltd boosted its holdings in shares of Merit Medical Systems by 252.6% in the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 336 shares during the period. Finally, Danske Bank A S purchased a new position in shares of Merit Medical Systems in the third quarter worth approximately $42,000. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Merit Medical Systems Trading Up 1.0%

Shares of MMSI stock opened at $72.14 on Wednesday. The firm has a market capitalization of $4.30 billion, a P/E ratio of 31.23, a price-to-earnings-growth ratio of 2.22 and a beta of 0.52. Merit Medical Systems, Inc. has a 1 year low of $59.74 and a 1 year high of $96.74. The firm’s fifty day simple moving average is $65.57 and its 200 day simple moving average is $73.35. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.10. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The company had revenue of $381.88 million for the quarter, compared to analyst estimates of $377.59 million. During the same period last year, the business posted $0.86 EPS. The business’s quarterly revenue was up 7.4% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, sell-side analysts predict that Merit Medical Systems, Inc. will post 3.62 EPS for the current year.

Insider Activity

In other Merit Medical Systems news, Director Lynne N. Ward sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $62.61, for a total value of $313,050.00. Following the completion of the transaction, the director owned 7,809 shares of the company’s stock, valued at $488,921.49. This represents a 39.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Brian G. Lloyd acquired 2,000 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were purchased at an average cost of $62.62 per share, for a total transaction of $125,240.00. Following the acquisition, the insider directly owned 2,000 shares in the company, valued at $125,240. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders own 0.70% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on MMSI shares. Citigroup restated an “outperform” rating on shares of Merit Medical Systems in a research report on Monday, April 20th. Compass Point set a $107.00 price objective on shares of Merit Medical Systems in a research report on Monday, April 20th. JPMorgan Chase & Co. cut their target price on shares of Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Weiss Ratings cut Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Finally, Robert W. Baird set a $83.00 price objective on shares of Merit Medical Systems in a research report on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Merit Medical Systems currently has an average rating of “Moderate Buy” and a consensus target price of $92.80.

Merit Medical Systems Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.